| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| Q9992 |
Injection, buprenorphine extended-release (sublocade), greater than 100 mg |
1,072 |
1,035 |
$1.85M |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
5,855 |
4,445 |
$881K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
14,328 |
11,271 |
$869K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,146 |
8,205 |
$838K |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
581 |
557 |
$766K |
| Q9991 |
Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg |
260 |
246 |
$464K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
8,863 |
6,941 |
$359K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,523 |
1,409 |
$154K |
| 80305 |
|
14,440 |
10,852 |
$133K |
| 90832 |
Psychotherapy, 30 minutes with patient |
902 |
838 |
$43K |
| 99222 |
Initial hospital care, per day, moderate complexity |
556 |
523 |
$34K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,524 |
3,079 |
$16K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
208 |
205 |
$15K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
134 |
121 |
$8K |
| 36415 |
Collection of venous blood by venipuncture |
1,592 |
1,486 |
$6K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
131 |
86 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
170 |
169 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
90 |
90 |
$2K |
| 99408 |
|
94 |
93 |
$2K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
19 |
19 |
$2K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
14 |
14 |
$1K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
14 |
12 |
$1K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
32 |
32 |
$1K |
| 99000 |
|
250 |
235 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
93 |
90 |
$921.30 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
97 |
97 |
$895.70 |
| 81002 |
|
314 |
303 |
$701.78 |
| 99218 |
|
12 |
12 |
$700.72 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
25 |
25 |
$595.98 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
12 |
12 |
$474.52 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
29 |
28 |
$419.38 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
12 |
12 |
$310.16 |
| 99407 |
|
18 |
17 |
$244.58 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
12 |
12 |
$230.30 |
| 96127 |
|
99 |
97 |
$217.10 |
| 99406 |
|
46 |
42 |
$189.86 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
35 |
31 |
$62.57 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
13 |
13 |
$48.60 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
29 |
24 |
$33.24 |
| 97802 |
|
273 |
249 |
$20.00 |
| 3077F |
|
14 |
12 |
$0.00 |
| 99051 |
|
331 |
299 |
$0.00 |
| 3078F |
|
229 |
215 |
$0.00 |
| 3008F |
|
366 |
338 |
$0.00 |
| 3074F |
|
253 |
234 |
$0.00 |
| 99224 |
|
50 |
28 |
$0.00 |
| 3079F |
|
34 |
33 |
$0.00 |
| 3075F |
|
18 |
17 |
$0.00 |
| 1000F |
|
17 |
17 |
$0.00 |